News | August 14, 2012

Positron Consolidates PET Radiopharmaceutical Facilities in Texas

August 14, 2012 — Positron Corp. announced the transfer, consolidation and integration of its radiopharmaceutical operations from the Crown Point, Ind. facility to its Lubbock, Texas site.

With the acquisition of Manhattan Isotope Technology (MIT), Positron gained the expertise, knowledge and radioactive materials facilities to manage all of the company's radiopharmaceutical and radioisotope development, production, processing and distribution mission. Since the acquisition of MIT earlier this year, Positron has made significant developments in the production requirements of key positron emission tomography (PET) radiopharmaceutical products, making the integration of production and facilities to the Lubbock facilities most favorable and advantageous for the company. 

MIT possesses the proper licenses, qualified staff, expertise, procedures and quality systems for all of Positron's pharmaceutical products. The transfer of all records, systems and equipment was completed in late July. The production of Indium Oxyquinoline will resume upon the modification of the company's current Texas radiation license to include Indium Oxine, with expected approval in August.

By locating all radioactive production to a single facility, Positron will simplify and improve regulatory compliance, radiation safety and quality procedures associated with the production of radioisotopes and radiopharmaceuticals. Additionally, the consolidation will significantly improve efficiencies, economics, and utilization throughout the company.

"With this consolidation, Positron can better realize the potential of our radiochemical and radiopharmaceutical segments. MIT will focus on key radioactive products allowing the company to accelerate and expand its offerings, while improving procedures and reducing operational costs. The integration and move to Lubbock will increase Positron's capabilities and further advance relationships with potential partners," said Patrick G. Rooney, CEO of Positron.

Positron is a molecular imaging healthcare company providing nuclear medicine technologies for the field of nuclear cardiology.

For more information: www.positron.com

 

Related Content

Colored areas of the brain represent regions where the loss of brain synapses in people with early-stage Alzheimer’s was greater than people with normal cognitive function.

Colored areas of the brain represent regions where the loss of brain synapses in people with early-stage Alzheimer’s was greater than people with normal cognitive function. Image courtesy of YaleNews.

News | PET Imaging | May 14, 2020
May 14, 2020 — New imaging technology allows scientists to see the widespread loss of brain synapses in early stages
The Society of Nuclear Medicine and Molecular Imaging's 2020 annual meeting has been reimagined, and is now the SNMMI 2020 Annual Meeting — Virtual Edition
News | Coronavirus (COVID-19) | April 30, 2020
April 30, 2020 — The Society of Nuclear Medicine and Molecular Imaging's 2020 annual meeting has been reimagined, and
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 U.S. Army Spc. Jonathon Hyde and Spc. Casymn Harrison from the 1434th Engineer Company, Grayling, Mich., Michigan National Guard, prepare patient rooms at TCF Regional Care Center in Detroit in advance of receiving COVID-19 patients, April 9, 2020 #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

U.S. Army Spc. Jonathon Hyde and Spc. Casymn Harrison from the 1434th Engineer Company, Grayling, Mich., Michigan National Guard, prepare patient rooms at TCF Regional Care Center in Detroit in advance of receiving COVID-19 patients, April 9, 2020. The TCF Center in Detroit has been converted into a 970-bed alternative care facility for COVID-19 patients by the Federal Emergency Management Agency, in partnership with the U.S. Army Corps of Engineers and Michigan National Guard. (Photo courtesy of U.S. Air National Guard photo by Master Sgt. Scott Thompson)

Feature | Coronavirus (COVID-19) | April 15, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Maximum-intensity PET projections at each time point for one rhesus monkey in the 89Zr-DFO-squaramide-anti-gD group.

Maximum-intensity PET projections at each time point for one rhesus monkey in the 89Zr-DFO-squaramide-anti-gD group. Image courtesy of Eric Berg, University of California, Davis, CA

News | PET Imaging | April 10, 2020
April 10, 2020 — Combining 89Zr-labeled antibodies with total-body...
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...